Acotiamide is a new prokinetic drug that is used to treat functional dyspepsia (FD). A sensitive and specific LC-MS-MS method has been developed and validated for the analysis of acotiamide in rat plasma. The assay involved a simple protein precipitation (PPT) step with methanol-acetonitrile (50:50, v/v) and a gradient elution using a mobile phase consisting of water containing 0.1% formic acid and methanol containing 0.1% formic acid. The analytes were chromatographed on a reversephase Agilent Zorbax XDB C 18 column (2.1 mm × 50 mm, 3.5 μm) with a flow rate of 0.50 mL/min. The analytes were monitored by tandem-mass spectrometry with positive electrospray ionization. The precursor-product transitions (m/z) in the positive ion mode were 451.4 → 271.3 and 386.2 → 122.2 for acotiamide and buspirone (internal standard, IS), respectively. The assay was shown to be linear over the range of 0.10-200 ng/mL, with a lower limit of quantification of 0.10 ng/mL. The method was shown to be reproducible and reliable with the inter-and intra-batch accuracy and precision were within ±15%. The assay has been successfully used for pharmacokinetic evaluation of acotiamide after intravenous and oral administration of 10 mg/kg acotiamide in rats. The oral absolute bioavailability (F) of acotiamide in rats was estimated to be 38.4 ± 13.5% with an elimination half-life (t 1/2 ) value of 9.11 ± 0.40 h.
Introduction
Functional dyspepsia (FD) has been defined as persistent or recurrent dyspepsia symptoms in the absence of underlying structural or metabolic disease (1) . In Rome III criteria, FD is further subdivided into categories of meal-unrelated epigastric pain syndrome (EPS) and meal-induced postprandial distress syndrome (PDS) (2) .
Acotiamide hydrochloride ( previously known as Z-338, N-[2-[bis (1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl) amino]thiazole-4-carboxamide monohydrochloride trihydrate, chemical structure shown in Figure 1 ), is a new prokinetic agent which exerts its gastroprokinetic activity by enhancement of acetylcholine release via acting as an antagonist on the M1 and M2 muscarinic receptors in the enteric nervous system and inhibiting acetylcholinesterase activity (3) (4) (5) (6) (7) (8) (9) .
Acotiamide has been approved in Japan in March 2013 and launched in Japan in June 2013, making it the world's first approved treatment for FD in patients diagnosed by Rome III criteria (10) . As a new studying hotspot, it is helpful to develop a sensitive and specific bioanalytical method to quantify acotiamide in biological fluids for the bioavailability study.
So far only a few authors have reported their bioanalytical assays of acotiamide in various sample matrices, including liquid chromatography with ultraviolet detection (LC-UV) (11) and ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) (12) . The HPLC-UV method is a general analytical method for determination of acotiamide in biological samples; however, this method showed lower sensitivity (only 2.5 ng/mL in dog plasma) and longer running times (>20 min) (11) . Recently, Patel et al. developed a UHPLC-Q-TOF-MS method for the quantification of acotiamide in rat plasma (12) , in which unsatisfactory sensitivity (1.31 ng/mL in rat plasma) was obtained. Most importantly, in terms of quantification of acotiamide in biological fluids, liquid chromatography-tandem mass spectrometry (LC-MS-MS) usually shows superior sensitivity and reproducibility. Thus, methodological improvements in the quantitative determination of acotiamide in rat plasma are in great need in pre-clinical trials for pharmacokinetic, efficacy and safety researches in pre-clinical trials.
The aim of this work is to develop a sensitive and specific bioanalytical method for the quantification of acotiamide in rat plasma using the LC-MS-MS technique. This method will be further validated and applied to a pharmacokinetic study in rats after intravenous and oral administration of acotiamide.
Experimental

Chemicals and reagents
Reference standard of acotiamide hydrochloride trihydrate (HPLC purity 99.1%, chemical structure shown in Figure 1 ) was purchased from RennoTech Co., Ltd. (Nanjing, Jiangsu, China). Buspirone (IS) was purchased from Sigma Chemical Co. (ST. Louis, Mo, USA). Sulfobutylether-beta-cyclodextrin (SBECD) was purchased from Cydex (Lenexa, KS, USA). Dimethyl sulfoxide (DMSO) of analytical grade was purchased from TEDIA (USA). Methanol and acetonitrile of HPLC grade were obtained from Fisher Co. Ltd. (Emerson, IA, USA). Formic acid and other reagents were of analytical grade and purchased from MREDA Chemical Reagent Company (Beijing, China). Ultrapure water was produced by a Milli-Q Reagent Water System (Millipore, MA, USA).
LC-MS-MS assay
The HPLC system consisted of an LC-20AD pump, a DGU-20 A 3 degasser, an SIL-20AC autosampler and a CTO-20A column oven (Shimadzu, Japan). Acotiamide and IS were separated on a reverse-phase Agilent Zorbax XDB C 18 column (2.1 mm × 50 mm, 3.5 μm), which was eluted with a gradient mobile phase consisting of water (A) and methanol (B) both containing 0.1% formic acid. A two-step gradient elution program was utilized as follows: 0.00 min 10% B, 0.30 min 10% B, 0.40 min 98% B, 1.80 min 98% B, 1.81 min 10% B and 3.30 min 10% B. The flow rate was set at 0.50 mL/min.
The column effluent was monitored using a 4000 QTRAP ® LC-MS-MS (AB Sciex, Toronto, Canada). The ESI source was operated in positive mode with the curtain, nebulizer and turbo-gas (all nitrogen) set at 20, 60 and 60 psi, respectively. The turbo-gas temperature was 550°C, and the ion spray needle voltage was 5,000 V. Optimal multiple reaction monitoring (MRM) was used to detect transition ions from a specific precursor ion to a product ion for acotiamide 
Preparation of standards and calibration curves
Separate stock solutions of acotiamide and IS (1.0 mg/mL) were prepared by dissolving appropriate amount of each reference standard in DMSO and were refrigerated until used. A series of acotiamide working standard solutions were prepared by appropriate dilutions of the stock acotiamide standard solution (1.0 mg/mL) with 50% methanol solution to obtain the following acotiamide concentrations: 2,000, 1,000, 500, 200, 50.0, 20.0, 5.00, 2.00 and 1.00 ng/mL. These standard solutions of acotiamide were used to spike blank rat plasma with acotiamide to yield calibration standards in plasma over the concentration range of 0.10-200 ng/mL. Briefly, the acotiamide spiking procedure involved transferring 5 μL aliquot of various acotiamide working standard solutions and 50 μL aliquot of blank plasma into 1.1 mL centrifuge tubes. Quality control (QC) samples were prepared in a similar manner at low, medium and high acotiamide levels (0.20, 5.00 and 160 ng/mL). The IS (Buspirone) working solutions (5 ng/mL) was prepared by diluting with methanol-acetonitrile (50:50, v/v). All the stock and working standard solutions were stored at 4°C prior to use.
Sample pretreatment
After being thawed at room temperature for ∼30 min and vortex for 30 s, aliquots of 50 μL rat plasma were mixed with 5 μL of 50% methanol solution (or standard or QC solution) and 150 μL of IS solution [5 ng mL −1 buspirone in methanol-acetonitrile (50:50, v/v)]. After being vortexed for 1 min and then centrifuged at 12,000g for 10 min, aliquots of 100 μL supernatants were transferred to HPLC vials. A volume of 10 μL of this solution was then injected onto the column.
Assay validation
According to the international guidelines (13, 14) , the method was validated in terms of the selectivity, linearity, lower limit of quantification (LLOQ), accuracy, precision, recovery, matrix effect, and stability. The selectivity was evaluated by analyzing six individual samples of blank rat plasma by comparison with the plasma-spiked analyte for endogenous interferences. Each blank sample was tested by the LC-MS-MS method to investigate potential interferences. Linear calibration curves in rat plasma were generated by plotting the peak area ratio of acotiamide to the IS versus the known plasma acotiamide concentrations over the range of 0.10-200 ng/mL. Slope, intercept and coefficient of determination values were estimated using least square regression analysis.
The LLOQ was selected as the lowest acotiamide plasma level on the calibration curve. The extraction recoveries of acotiamide from rat plasma (expressed as a percentage) were calculated as the ratio of the slope of a calibration curve for acotiamide in spiked plasma to that in spiked mobile phase.
QC plasma samples containing low, medium and high acotiamide concentrations were used to evaluate the precision and accuracy of the assay method. The intra-batch assay precision and accuracy were obtained by analyzing six replicates of the QC samples in duplicate using a calibration curve constructed on the same day. The inter-batch assay precision and accuracy were obtained by analyzing six QC samples in duplicate using calibration curves constructed on three different days. The assay precision was reflected by the relative standard deviation (RSD %), and the assay accuracy was reflected by the relative percentage error from the theoretical drug concentrations.
Matrix effects from endogenous substances present in processed rat plasma may cause ion suppression or enhancement of the signal. Matrix effects were assessed by comparing the peak areas of acotiamide after addition of low, medium and high concentrations of acotiamide to (A) mobile phase and (B) the supernatant of processed blank plasma (15) . These studies were conducted with six different lots of rat plasma. The peak area ratio of B/A (as a percentage) or the percentage matrix factor was used as a quantitative measure of the matrix effect.
The stability of acotiamide in rat plasma was investigated at three QC levels, as described in the 'Preparation of standards and calibration curves' section. Stability tests of the analyte were performed on six replicates of three QC concentrations after (a) three freeze (−20°C) and thaw (20°C) cycles, (b) processed samples at 20°C for 24 h and (c) stored at −80°C for a month.
Pharmacokinetic application
The protocol of this animal study was approved by the Animal Care and Use Committee of Qingdao University ( permission number: 2014161; date of expiration: May 11, 2016; Qingdao, Shandong, China). Six male SD rats weighing 200-250 g were purchased from Beijing Vital River Laboratories Co., Ltd (Beijing, China). The rats were certified and had not been dosed with any pharmaceutical before the experiment. The rats were housed under standard conditions and had ad libitum access to water and a standard laboratory diet. Polyethylene cannulas were implanted in the femoral vein 2 days before the experiment while the rats were anesthetized with pentobarbital (50 mg/kg, intravenous). The cannulas were externalized at the back of the neck and filled with heparinized saline (20 units/mL) to prevent blood clotting.
Each rat was housed individually in a rat metabolic cage and was not restrained at any time during the study. The rats were fasted for 12 h before experiments with the exception of free access to water. The dosing solution with acotiamide concentration of 2.0 mg/mL was prepared by dissolving appropriate amount of acotiamide in DMSO-30% SBECD (5:95, v/v). The actual concentration of acotiamide in the dosing solution had been confirmed using the same LC-ESI-MS-MS method to be within the criteria (±15%) comparing with the designed dose concentration (2.0 mg/mL). The actual intravenous and oral doses of acotiamide were both 10 mg/kg, which was originated from the human dose level used in the clinical trial (16) , and the dose volume was 5.0 mL/kg. After intravenous administration of 10 mg/kg acotiamide through tail vein, aliquots of 0. . Heparinized blood was centrifuged at 12,000g at room temperature for 5 min to obtain plasma, which was stored at −80°C until analysis.
Pharmacokinetic parameters including half-life (t 1/2 ), maximum plasma time (t max ) and concentration (C max ), area under concentration-time curve (AUC last and AUC Inf ), clearance (Cl), steady-state volume of distribution (V ss ), and the mean residence time (MRT) of acotiamide were analyzed by a non-compartmental method using WinNonlin Version 5.1 (Pharsight Corporation, Mountain View, USA). All results were expressed as arithmetic mean ± standard deviation (SD).
Results
Mass spectrometry and chromatography
This study describes the development of a sensitive and specific LC-MS-MS assay for the determination of acotiamide concentrations in rat plasma. The full-scan product ion mass spectra of acotiamide and buspirone (IS) are shown in Figure 1 . Mass chromatograms of acotiamide and IS obtained by extraction of blank rat plasma, blank plasma spiked with acotiamide and IS and actual unknown plasma samples obtained in rats after intravenous and oral injection of acotiamide (dose 10 mg/kg) are shown in Figure 2 . The chromatographic running time for the plasma samples was 3.3 min. The retention times for acotiamide and IS were 1.70 and 1.67 min, respectively. The chromatograms show the baseline separation of acotiamide and the IS without any interference from endogenous plasma components.
Method validation
Calibration standards were prepared by spiking 5 μL of the appropriate standard solutions of acotiamide to 50 μL of blank rat plasma. Plasma concentrations of acotiamide were 0.10, 0.20, 0.50, 2.00, 5.00, 20, 50, 100 and 200 ng/mL. The peak area (y) and concentration of acotiamide (x) were subjected to a weighted (1/X 2 ) least squares linear regression analysis to calculate calibration equation and correlation coefficients. The linear ranges of acotiamide in rat plasma were from 0.10 to 200 ng/mL. Typical equations for the standard curves were y = 6.53E − 02x + 6.42E − 04 (r = 0.9984). The LLOQ was 0.10 ng/mL. The LLOQ of acotiamide in this study was 0.10 ng/mL in rat plasma, as opposed to 2.5 ng/mL (11) and 1.31 ng/mL (12) .
To determine the intra-batch precision of the method, three plasma samples with the concentrations of 0.20, 5.00 and 160 ng/mL were analyzed six times on the same day. To determine the inter-batch precision and the accuracy, further three plasma samples were run on each of three different days. Table I summarizes the intra-and inter-batch precision and accuracy for acotiamide from QC samples in rats.
The recoveries of acotiamide at three concentration levels of 0.20, 5.00 and 160 ng/mL had been determined to be 90.4, 91.0 and 93.9%, with RSD of 5.04, 1.24 and 0.51%, respectively. The data indicated that the recoveries of acotiamide from rat plasma were concentration-independent in the concentration range evaluated and the recoveries were acceptable for the pharmacokinetic analysis. A mean percentage matrix effect value of 91.3% for acotiamide (RSD all within 7.19%) was calculated and found to be independent of acotiamide plasma concentration and rat plasma lot. This result is in agreement with international guidelines and indicates low ion suppression.
The described stability data are summarized in Table II . The results indicated that acotiamide at the three concentrations tested had acceptable stabilities after three cycles of freeze-thaw, at room temperature for 24 h and at −80°C for 1 month with the % relative error (RE) values being within ±15%.
Application of the assay method
The analytical procedures described above had been used to quantify acotiamide in the plasma samples obtained from the rats, which were intravenously and orally administered a single dose of 10 mg/kg Figure 2 . Typical chromatograms of (A) blank rat plasma; (B) blank rat plasma spiked with acotiamide (0.10 ng/mL, LLOQ) and IS; (C) an actual rat plasma sample collected at 2 min after intravenous administration of 10 mg/kg acotiamide (determined concentration 29.1 ng/mL with 100-fold dilution) and (D) an actual rat plasma sample collected at 30 min after oral administration of 10 mg/kg acotiamide (determined concentration 26.9 ng/mL with 10-fold dilution). This figure is available in black and white in print and in color at JCS online. acotiamide. The plasma concentration-time profiles of acotiamide in rats are shown in Figure 3 , and the main pharmacokinetic parameters of acotiamide after intravenous and oral administration are presented in Table III .
Discussion
Mass spectrometry
In the full-scan Q1 mass spectrum (Figure 1 Other conditions such as ion spray voltage, curtain gas pressure, nebulizer gas pressure, heater gas pressure, source temperature and collision energy were further optimized to improve the sensitivity and response stability of acotiamide.
Chromatography
During the optimization of chromatographic conditions, acotiamide was extensively retained on several kinds of columns due to its physical-chemical properties. To achieve symmetric peak shapes and short chromatographic running times, the mobile phase consisting of methanol with 0.1% formic acid and water with 0.1% formic acid was used on a Zorbax XDB C 18 column.
Choice of internal standard
An internal standard (IS) is usually required in the LC-MS-MS analysis to rectify the probable error in sample processing and determination. Usually an isotope-labeled IS is the optimal choose; however, it is usually very expensive and not easy to obtain for most researchers all over the world. In this study, buspirone, a readily available compound, was selected as the IS, which displays similar chromatographic retention behavior (t R = 1.67 min) with acotiamide and high efficiency (>80%). In addition, there were no interferences of IS from acotiamide and endogenous substances.
Sample pretreatment
In this study, two frequently used pretreatment methods were investigated: PPT and liquid-liquid extraction. The Liquid-liquid extraction method provided similarly "clean" samples with those from the PPT method in terms of selectivity and matrix effect, but obviously the latter is a more simple method of sample preparation and has been widely used for the analysis of analytes in plasma. Therefore, methanol, acetonitrile and a mixed solution of methanol-acetonitrile (50:50, v/v) were evaluated as the protein precipitator. The results indicated that higher efficiency and recoveries of acotiamide (>90%) when a mixed solution of methanol-acetonitrile (50:50, v/v) was used as protein precipitator as compared with methanol or acetonitrile. 
